TY  - JOUR
T1  - HOrmone replacement therapy for secondary prevention of coronary heart disease
AU  - Pan CX, Boal J, et al
Y1  - 1999/03/03
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303
JO  - JAMA
SP  - 794
EP  - 797
VL  - 281
IS  - 9
N2  - 
Despite the appropriate randomization, blinding, and intention-to-treat
analysis, we are concerned that, during the trial, subjects in the
control and HRT groups were differently exposed to agents that could
affect the primary study outcomes. For example, the authors noted that
more women in the control group began treatment with lipid-lowering
agents (primarily statins) during the trial, and they astutely adjusted
for low-density lipoprotein levels during their analysis. However,
since statin use over an average of 5 years decreases coronary events
and coronary deaths in patients with CHD who have high and normal
cholesterol levels,2- 4 this differential utilization could
still bias the results toward not showing a difference between the 2
groups.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303
ER  -